Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–8 of 8 results
Advanced filters: Author: Laetitia Seguin Clear advanced filters

  • A limited percentage of patients with non-small cell lung cancer respond to immunotherapy. Here the authors show that HEI3090, a chemical positive modulator of the purinergic P2RX7 receptor, promotes IL-18 mediated anti-tumor immune responses and sensitizes lung cancer to anti-PD-1 therapy in preclinical models.

    • Laetitia Douguet
    • Serena Janho dit Hreich
    • Valérie Vouret-Craviari
    ResearchOpen Access
    Nature Communications
    Volume: 12, P: 1-17

  • Raf kinase activity is deregulated in cancers and is thought to promote tumor growth by inducing proliferation signaling through MEK/Erk. This report identifies a new role for c-Raf independent of MEK/Erk and relying on phosphorylation of Ser338. Phospho–C-Raf interacts with the mitotic kinases Aurora-A and Plk1, activating the latter to promote mitotic progression and increase cell division, and this pathway is a crucial mediator for the protumorigenic effect of c-Raf in vivo.

    • Ainhoa Mielgo
    • Laetitia Seguin
    • David A Cheresh
    Research
    Nature Medicine
    Volume: 17, P: 1641-1645

  • Tumors hijack cellular pathways to evade the effects of cancer therapy. Here, Advaniet al. show that DNA damage-induced phosphorylation of CRAF Serine 338 triggers DNA repair by recruiting CHK2, highlighting a role for CRAF independent from its canonical function as a kinase.

    • Sunil J. Advani
    • Maria Fernanda Camargo
    • David A. Cheresh
    ResearchOpen Access
    Nature Communications
    Volume: 6, P: 1-8

  • Seguin et al demonstrated in glioblastoma patient-derived stem cells that a subset of glioblastoma tumours is dependent on macropinocytosis mediated survival through a Galectin-3/RAB10/beta 1 integrin axis. They used both genetic and pharmacologic inhibition of Galectin-3 in vivo and in vitro to identify underlying mechanisms and define a Galectin-3/macropinocytosis molecular signature, which could inform the development of anti-tumour therapeutic strategies.

    • Laetitia Seguin
    • Soline Odouard
    • Érika Cosset
    ResearchOpen Access
    Communications Biology
    Volume: 4, P: 1-17

  • Cheresh and colleagues delineate a pathway that regulates tumour cell stemness and resistance to therapy. They find that the unliganded integrin αvβ3 is able to promote cancer cell self-renewal, tumour initiation and resistance to EGFR inhibitors by binding KRAS and RalB to activate the NF-κB pathway.

    • Laetitia Seguin
    • Shumei Kato
    • David A. Cheresh
    Research
    Nature Cell Biology
    Volume: 16, P: 457-468